Clin2
NCT05724121Possibly a fitRecruiting

Study heart rhythm changes during BTK or venetoclax treatment

Chronic Lymphocytic Leukemia (CLL)Waldenstr(SqrRoot)(Delta)m s MacroglobulinemiaMantle Cell LymphomaSudden Cardiac DeathCardiac ArrhythmiasHematologic Malignancies

Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.

This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
135 people
Ages
18 years to 110 years
Study type
Observational

Who can take part

  • You are currently taking, or plan to start, a BTK inhibitor or venetoclax
  • You are 18 years or older
  • You can attend study visits and follow the study plan for the whole study
  • You understand the study and are willing to sign a consent form
  • You can be reached/available for study procedures during treatment

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07711327Not yet recruiting
Heart rhythm in blood cancer patients starting new treatments

This study looks at whether starting certain blood cancer treatments (BTK inhibitors or others like venetoclax) affects heart rhythm. It focuses on people with specific blood cancers who are starting a new treatment, to check for new or worsening atrial fibrillation.

Duarte, California
NCT06151730Recruiting
Managing blood pressure and heart risks during BTKi treatment

This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.

Rochester, Minnesota
NCT07592481Not yet recruiting
Blood Pressure Monitoring During BTK Inhibitor Treatment

This study uses a connected blood pressure monitor to track blood pressure changes in patients with blood cancers who are starting a type of targeted drug called a BTK inhibitor. Researchers want to see if home monitoring helps catch and manage blood pressure changes early.

NCT03557619Recruiting· Phase 1
Venetoclax test in women with specific non-Hodgkin lymphomas

This Phase 1 study tests how venetoclax affects certain hormone pills (ethinyl estradiol and levonorgestrel) in women with different non-Hodgkin lymphomas. It’s mainly looking at safety and drug interactions, which could help guide treatment for people who need hormone-based contraception.

Detroit, Michigan
NCT06211413Enrolling by invitation
Tracking heart issues in CLL patients on BTK inhibitors

This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.

Philadelphia, Pennsylvania
NCT03986034Recruiting· Phase 2
Venetoclax study in relapsed CLL using early tumor tracking

This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.

Bethesda, Maryland

Hear when a new Mantle Cell Lymphoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.